Member Info for stu485

No, not yet.
Good luck with your call.

... I have.
Will share response if I get one and it's informative. I'm not hopeful !

Rather than forming investment judgements on , interpretation, tweets and rumour, how about considering the known facts!

RNS 13th Jan - "as of the 11th Jan 2021 GlobalCo has three months to exercise an option to licence"
That deadline has now passed and no such announcement has been made!

If you want to read into the RNS 1st April that GlobalCo will take up the licence following negotiation, then you may prove to be correct BUT you're ignoring a key FACT staring you in the face!

I like BOP do not want the less experienced to make what could be regretful investment decisions.
PS Take note of BoP, in my opinion the most balanced on this board.

All IMO

...follow the money!

Thanks RG.

There should be an RNS next week to state if Global Co have taken up the "Option" or not.
That information is of material importance and it was stated to shareholders through a previous RNS that it would be disclosed within 3 months of 11th Jan.
The most recent RNS does not contain this information and hence it is still outstanding.
IMO

In my opinion, I suspect Middle East funds buying in soon. No inside knowledge ,just my research.
For interest, all trades today are buy's albeit small.

...let me put it another way.
There's nothing within today's RNS confirming Hemo aren't the party negotiating to progress to licensing.
Yes I am reading the RNS literally and without interpretation.

It could well be the wording was not intended to read how it does and I do hope that's the case, as I'm deep under water with this one! However, personally I believe the company would not be so obtuse without reason.

I’m sorry, it still reads either or when considering both first (old) and second paragraph.

Read it carefully and you will see it’s still either Global Co OR the company that may license !!!

ST- Do you think Beckman intend to replace their existing Covid testing solutions with our's overnight or phased over time?

Obviously the answer one way or the other would make a massive change to forecast SP.

Seems to be screaming out to me, the Hospital trial is not going to deliver good news as too late in infection for the specific treatment and therefore all eggs in the basket of earlier intervention. No problem with that discounting the probable big dip in sp on such news.
The other message I'm reading is, the emphasis on the home trial being an achievement in itself regardless of the drug efficacy, to the extent where I could see it being used within a future RNS to soften the blow of poor home trial results to try and support some shareholder confidence within the future direction of the company...novel trials.
I want to be completely wrong on both counts for my own financial interest and the greater good of a successful treatment.
Just my thoughts and interpretation.